Bristol-myers squibb begins tender offer to acquire amylin pharmaceuticals, inc. Full Text
Bristol Myers-Squibb, 07/11/2012
Bristol–Myers Squibb Company is commencing, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). Bristol–Myers Squibb announced on Friday, June 2012, its intent to acquire Amylin.



